ABSTRACT
Objective To investigate the levels of HBsAg and HBV DNA in different clinical stages. Methods Serum samples of 246 patients, without accepting antiviral therapy, from the second affiliated anhui medical univrsity were collected from 2012.1 to 2013.5. Among the enrolled patients, 41 cases with chronic HBV-carrier (ASC), 99 cases with chronic hepatitis B patients (CHB), 70 cases with liver cirrhosis (LC), and 36 cases with primary liver cancer (HCC) were included. Results Levels of HBsAg in the group of ASC, CHB, LC, HCC were 135 280.00 (1 788.80 ~ 51 820.00) IU / mL, 8 218.00 (1 644.60 ~ 266 700.80) IU / mL, 1 280.38 (265.70~2 375.00) IU / mL, and 925.10(135.05 ~ 2 381.8) IU / mL, respectively. Positive correlations were observed between HBsAg tire and HBV DNA levels (rs = 0.332, P = 0.000), and negative correlations were doserved between HBsAg leve and age(rs = -0.496,P = 0.000). Conclusions The level of HBsAg in serum decreased progressively from the group of ASC to CHB, LC and HCC, the positive correlation between levels of HBsAg and HBV DNA, and the negative correction between HBsAg level and age were demonstrated.
ABSTRACT
Objective To discuss the value of TAI, TAE and PEI treatments for intermediate and advanced stages of hepatic cancers.Methods Conventional TAE, TAI, PEI perfusion chemotherapy and mulitiple percutaneous transhepatic injection of pure alcohol under guidance of fluoroscopy and CT were used for different cases. Results Follow up 1-3 year. 1,2,3 year survival rates were 60.3%, 28.6%, 17.3% respectively.Conclusions Combination interventional treatment in intermediate and advanced stages of hepatic is very important outcoming with high efficacy.